A is the answer and the winners are Otiegha and Solace.
Metformin is a biguanide which, unlike sulphonylureas, is not associated with
weight gain. It is therefore an appropriate antidiabetic for GL who is obese.
It increases insulin sensitivity and increases the utilisation of glucose. It does
not interfere with insulin release. It may cause lactic acidosis. During treatment
metformin causes conversion of glucose to lactate in the intestinal mucosa;
lactate is transported to the liver where it is normally metabolised. High plasma
concentrations of metformin such as in renal impairment or high lactate
concentrations in blood caused by liver disease and alcohol abuse lead to the
inability by the liver to clear the lactate. Metformin should not be used in renal
impairment, and diabetic patients receiving metformin should have their renal
function monitored to exclude renal function deterioration, which may warrant
withdrawal of metformin.
A is the answer and the winners are Otiegha and Solace.
Metformin is a biguanide which, unlike sulphonylureas, is not associated with
weight gain. It is therefore an appropriate antidiabetic for GL who is obese.
It increases insulin sensitivity and increases the utilisation of glucose. It does
not interfere with insulin release. It may cause lactic acidosis. During treatment
metformin causes conversion of glucose to lactate in the intestinal mucosa;
lactate is transported to the liver where it is normally metabolised. High plasma
concentrations of metformin such as in renal impairment or high lactate
concentrations in blood caused by liver disease and alcohol abuse lead to the
inability by the liver to clear the lactate. Metformin should not be used in renal
impairment, and diabetic patients receiving metformin should have their renal
function monitored to exclude renal function deterioration, which may warrant
withdrawal of metformin.
E
D
D
B
A
A
A